Alternative lengthening of telomeres in human glioma stem cells

Stem Cells

Volumn 29, Issue 3, 2011, Pages 440-451

  Silvestre, David C ^a,b,c   Pineda, José R ^a,b,c   Hoffschir, Françoise ^a,b,c   Studler, Jeanne Marie ^b   Mouthon, Marc André ^a,b,c   Pflumio, Françoise ^a,b,c   Junier, Marie Pierre ^b   Chneiweiss, Hervé ^b   Boussin, François D ^a,b,c  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b INSERM   (France)

^c Universite Paris Sud   (France)

Author keywords

Alternative lengthening of telomeres; Human glioma; Radioresistance; Tumor stem like cells

Indexed keywords

TELOMERASE;

ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CELL ISOLATION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; IONIZING RADIATION; MOUSE; NONHUMAN; PHENOTYPE; PROMYELOCYTIC LEUKEMIA; RADIOSENSITIVITY; TELOMERE;

ADULT; AGED; ANIMALS; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MIDDLE AGED; NEOPLASTIC STEM CELLS; TELOMERE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

MUS;

EID: 79953013144     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.600     Document Type: Article

References (47)

1. de Lange T. Protection of mammalian telomeres. Oncogene 2002;21:532-540.
2. Klapper W, Shin T, Mattson MP. Differential regulation of telomerase activity and TERT expression during brain development in mice. J Neurosci Res 2001;64:252-260. (Pubitemid 32385693)
3. Kruk PA, Balajee AS, Rao KS et al. Telomere reduction and telomerase inactivation during neuronal cell differentiation. Biochem Biophys Res Commun 1996;224:487-492. (Pubitemid 26268214)
4. Bryan TM, Englezou A, Gupta J et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14:4240-4248.
5. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-2710. (Pubitemid 350070717)
6. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Oncol 2002;64:259-273. (Pubitemid 35254019)
7. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002;2:616-626. (Pubitemid 37328928)
8. Hakin-Smith V, Jellinek DA, Levy D et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003;361:836-838. (Pubitemid 36331849)
9. Henson JD, Hannay JA, McCarthy SW et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217-225. (Pubitemid 40075798)
10. Chen YJ, Hakin-Smith V, Teo M et al. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 2006;66:6473-6476. (Pubitemid 44085598)
11. McDonald KL, McDonnell J, Muntoni A et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 2010;69:729-736.
12. Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-7021. (Pubitemid 39331011)
13. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
14. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828. (Pubitemid 37187480)
15. Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007;67:8980-8984. (Pubitemid 47535877)
16. Marian CO, Cho SK, McEllin BM et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010;16:154-163.
17. Shervington A, Lu C, Patel R et al. Telomerase downregulation in cancer brain stem cell. Mol Cell Biochem 2009;331:153-159.
18. Patru C, Romao L, Varlet P et al. CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 2010;10:66.
19. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
20. Varlet P, Soni D, Miquel C et al. New variants of malignant glioneuronal tumors: A clinicopathological study of 40 cases. Neurosurgery 2004;55:1377-1391; discussion 1391-1372.
21. Pollard SM, Yoshikawa K, Clarke ID et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009;4:568-580.
22. Pennarun G, Granotier C, Hoffschir F et al. Role of ATM in the telomere response to the G-quadruplex ligand 360A. Nucleic Acids Res 2008;36:1741-1754. (Pubitemid 351426123)
23. Cesare AJ, Kaul Z, Cohen SB et al. Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat Struct Mol Biol 2009;16:1244-1251.
24. Dunham MA, Neumann AA, Fasching CL et al. Telomere maintenance by recombination in human cells. Nat Genet 2000;26:447-450.
25. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: Models, mechanisms and implications. Nat Rev Genet 2010;11:319-330.
26. Bryan TM, Englezou A, Dalla-Pozza L et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997;3:1271-1274. (Pubitemid 27508830)
27. Cesare AJ, Griffith JD. Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol 2004;24:9948-9957. (Pubitemid 39458820)
28. Wang RC, Smogorzewska A, de Lange T. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 2004;119:355-368. (Pubitemid 39423838)
29. Yeager TR, Neumann AA, Englezou A et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999;59:4175-4179. (Pubitemid 29418720)
30. Lee J, Kotliarova S, Kotliarov Y et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403. (Pubitemid 43668737)
31. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-765. (Pubitemid 44949605)
32. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255:1707-1710.
33. Hemmati HD, Nakano I, Lazareff JA et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003;100:15178-15183. (Pubitemid 37518036)
34. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
35. Beier D, Hau P, Proescholdt M et al. CD133(+) and CD133(-) glioblastoma- derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67:4010-4015. (Pubitemid 46815044)
36. Chen R, Nishimura MC, Bumbaca SM et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010;17:362-375.
37. Son MJ, Woolard K, Nam DH et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009;4:440-452.
38. Lee J, Son MJ, Woolard K et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008;13:69-80. (Pubitemid 350309742)
39. Nakano I, Kornblum HI. Brain tumor stem cells. Pediatr Res 2006;59:54R-58R.
40. Wurdak H, Zhu S, Romero A et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 2010;6:37-47.
41. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50.
42. Zhou BB, Zhang H, Damelin M et al. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-823.
43. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003;13:1549-1556. (Pubitemid 37078413)
44. Bae NS, Baumann P. A RAP1/TRF2 complex inhibits nonhomologous end-joining at human telomeric DNA ends. Mol Cell 2007;26:323-334. (Pubitemid 46687097)
45. Jeyapalan JN, Varley H, Foxon JL et al. Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome. Hum Mol Genet 2005;14:1785-1794. (Pubitemid 41418050)
46. Bechter OE, Shay JW, Wright WE. The frequency of homologous recombination in human ALT cells. Cell Cycle 2004;3:547-549. (Pubitemid 40278184)
47. Londono-Vallejo JA, Der-Sarkissian H, Cazes L et al. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 2004;64:2324-2327. (Pubitemid 38523881)